GSK’s new company Haleon will have a site in Nyon
Share this article
The pharmaceutical group GlaxoSmithKline creates Haleon, a new company from the separation of its consumer healthcare business.
This entity will have a site in the commune of Prangins, part of the district of Nyon.
The site currently employs 1,000 people in Prangins and produces 252 million units per year, including the medicines Voltaren and Otrivin.
Haleon will serve more than 100 markets worldwide and has an established presence in all key channels, including one of the largest networks and coverage of pharmacies globally with leadership in Europe and strong partnerships with mass retail and pharmacy chains in the US.
The company is the global leader in each of the major categories in which it operates – Therapeutic Oral Health; Vitamins, Minerals and Supplements; Pain Relief; Respiratory Health; and Digestive Health. The portfolio comprises global power brands such as Sensodyne, Panadol, Advil, Voltaren, Theraflu, Otrivin, and Centrum; and iconic, local strategic brands such as TUMS, ENO, Flonase, ChapStick and Emergen-C.
The name is a combination of Old English words meaning “healthy” and “strong”.